Antares To Start Testing ATRS-1902 With Injector Technology In Patients With Adrenal Crisis

  • The FDA has accepted Antares Pharma Inc's ATRS Investigational New Drug Application (IND) for ATRS-1902 for adrenal crisis rescue. 
  • The active IND enables Antares to initiate a Phase 1 study for ATRS-1902 for acute adrenal insufficiency, known as an adrenal crisis, in adults and adolescents.
  • Adrenal crisis is a potentially fatal condition associated mainly with an acute deficiency of cortisol, which is a hormone produced and released by the adrenal gland. It commonly occurs in patients with long-term adrenal insufficiency.
  • The IND application includes a protocol for an initial study to compare the pharmacokinetic (PK) profile of the Company's formulated hydrocortisone versus Solu-Cortef, expected to initiate in 2H 2021. 
  • A second study will then be conducted utilizing Antares' auto-injector technology.
  • The company expects to file a marketing application to the FDA by the end of 2022.
  • Price Action: ATRS shares are down 1.04% at $4.23 during the market session on the last check Thursday.
  • Related content: Benzinga's Full FDA Calendar.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareSmall CapFDAGeneralBriefsInvestigational New Drug Application
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!